NeurogesX Brings Astellas On Board To Launch Pain Patch in Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Qutenza patch is poised to compete with Lyrica and Lidoderm for neuropathic pain in Europe and the U.S.
You may also be interested in...
NeurogesX Gets $40 Million To Fund U.S. Launch Of Qutenza Through Royalty Deal
Cowen Healthcare Royalty Partners provides the $40 million in exchange for royalties and sales milestones from areas controlled by Astellas.
NeurogesX Gets $40 Million To Fund U.S. Launch Of Qutenza Through Royalty Deal
Cowen Healthcare Royalty Partners provides the $40 million in exchange for royalties and sales milestones from areas controlled by Astellas.
XenoPort’s Second Pain Failure Puts Heat On Restless Legs
With generic Requips making headway in restless legs, investors had counted on cashing in on diabetic neuropathy.